Healthcare

Chimeric Therapeutics Limited (ASX:CHM)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 0.3150.005 (1.613%)

(as on 2021-10-24 00:05:19)

Market Cap : AUD 105.035 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.31 0.315 0.315 0.305L 0.315 H 0.24L 0.44 H
Last Trade 0.315
Change% 1.6129
52 W H/L 0.44/0.24
EBITDA 0
NPAT After Abnormal Items -15.114 M
Equity 25.131 M
ROE% -60.14%
Total Liabilities 11.374 M
Total Revenue 2,646
Cash and Cash Equivalents 22.41 M

Stock Information

Share price 0.315
Market Cap 105.035 M
Price/Gross Cash Flow -5.40
Dividend Yield Excluding Special 0.00%
Ending Shares 196.833 M
52-Week Range 0.24-0.44
P/E ratio 0.000
Sector P/E --
EPS -8.00
EV/EBITDA --
Net Profit Margin (%) -571,190.89%
Gross Cash Flows Per Share -0.06
Net Gearing -89.17%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.06
Sales Per Share 0.00
Book Value Per Share 0.13

Announcements

Heading Date/Time
FIRST MILESTONE ON PATH TO CDH17 CAR T CLINICAL TRIAL  22/10/2021 9:15AM
Quarterly Activities/Appendix 4C Cash Flow Report  21/10/2021 10:02AM
Notice of Annual General Meeting/Proxy Form  18/10/2021 5:50PM
Corporate Governance Statement  29/09/2021 5:31PM
Appendix 4G  29/09/2021 5:31PM
Annual Report to shareholders  29/09/2021 5:31PM
CHM 1101 data accepted for presentation at SNO meeting  29/09/2021 9:31AM
Notification regarding unquoted securities - CHM  23/09/2021 5:04PM
European patent granted for CLTX technology used in CHM 1101  23/09/2021 10:25AM
Cellular therapy experts join Chimeric CI-SAB  15/09/2021 9:54AM
Partnership with OncoBay Clinical to advance CHM 1101  02/09/2021 9:40AM
Initial Director's Interest Notice - JC  02/09/2021 8:27AM
Notice under section 708A  31/08/2021 5:27PM
Preliminary Final Report  31/08/2021 12:49PM
Chimeric Appoints Jennifer Chow as CEO & MD  30/08/2021 10:19AM
Notification regarding unquoted securities - CHM  27/08/2021 5:29PM
Application for quotation of securities - CHM  27/08/2021 5:22PM
Application for quotation of securities - CHM  25/08/2021 1:43PM
Release of ordinary shares from escrow  25/08/2021 1:09PM
IND clearance received from US FDA for CHM 1101  20/08/2021 9:31AM
Change of Director's Interest Notice - GM  09/08/2021 9:19AM
Dr Yi Lin appointed to Cellular Immunotherapy SAB  06/08/2021 9:36AM
Chimeric Therapeutics CDH17 Investor Webinar  28/07/2021 9:48AM
Chimeric licenses novel solid tumor CAR T therapy from Penn  28/07/2021 8:21AM
Quarterly Activities/Appendix 4C Cash Flow Report  27/07/2021 2:51PM
Initial Director's Interest Notice - GM  05/07/2021 4:12PM
Celgene Veteran Dr George Matcham Appointed to Board  05/07/2021 9:05AM
Dr Li Ren Joins as Vice President Technical Operations  25/06/2021 9:40AM
Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial  24/05/2021 8:54AM

Similar Companies

Related Articles

Load More

About Company

Chimeric Therapeutics Limited (ASX:CHM)

Clinical-stage oncology player Chimeric Therapeutics Limited (ASX:CHM) is developing revolutionary CAR-T cell therapies for the management of solid cancers. The Company’s CAR T cell therapy uses the chlorotoxin (CLTX) peptide as the chimeric antigen receptor (CAR) tumour recognition domain. Besides, Chimeric has established potent antitumor activity against the most challenging form of brain cancer known as glioblastoma (GBM).

The CLTX-CAR-T technology includes a novel CAR-T recognition domain, CLTX, that is derived from the poison of a scorpion. Currently, the Company is performing Phase 1 clinical studies in GBM at the City of Hope Cancer Centre in Los Angeles, California.

Chimeric Therapeutics is working to become a leader in cell therapy and develop life-transforming treatments. The Company believes that cellular therapies have the potential to cure cancer, and the Company will be able to bring the promise of cell therapy to life for more patients by combining their expertise in cell therapies with the world’s most innovative scientists.

Chimeric has licensed the exclusive global intellectual property (IP) rights for the CLTX CAR T cell therapy, currently under development for patients suffering from progressive and recurrent GBM.

CLTX CAR T cell therapy is also being investigated for the treatment of other solid tumours like colorectal cancer, melanoma, prostate cancer, and small cell lung cancer.

Chimeric’s CLTX CAR T therapy

The CLTX CAR T cell therapy is possibly a best-in-class therapy that has the potential to address the high unmet need of recurrent/progressive GBM patients. The study for developing the IP covering the CLTX CAR T cell therapy was performed at City of Hope.

CLTX CAR T cells have shown significant antitumor action against GBM in preclinical studies without exhibiting any off-tumour identification of normal human cells and tissues. The findings of preclinical studies reveal a potentially ideal safety and efficacy profile of the therapy.

Currently, Chimeric Therapeutics is actively engaged in developing its product pipeline with pioneering cell therapies to treat different types of cancer.

Corporate Information

company address Level 3, 62 Lygon Street, CARLTON SOUTH, VIC, AUSTRALIA, 3053

company phone+61 3 98245254

company email[email protected]

company websitehttp://www.chimerictherapeutics.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 --

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-09-28 2022
Report (Prelim) 2022-08-30 2022
Report (Interim) 2022-02-25 2022

Financials

Breakdown 30/06/2021 30/06/2020
Trading Revenue 2,646 --
Other Revenue 0 0
Total Revenue 2,646 0
Interest Income 0 0
Interest Expenses -5,877 0
Expenses -15.108 M 0
EBITDA -15.105 M 0
Depreciation and Amortization -2,633 0
Depreciation -2,633 0
Amortisation 0 0
EBIT -15.108 M 0
Pre Tax Profit -15.114 M 0
Tax Expense 0 0
Net Profit After Tax -15.114 M 0
Minority Interest 0 0
Preference Dividend 0 0
Net Abnormal Items 0 0
Reported Net Profit After Abnormal Items -15.114 M 0
Ending Shares 196.833 M 330.526 M
Weighted Average Shares 181.896 M 330.526 M
EPS After Abnormal Items (cents) -8.31 0
Breakdown 30/06/2021 30/06/2020
Total Current Assets 22.665 M 36.381 M
Total Non Current Assets 13.84 M 15.186 M
Total Assets 36.505 M 51.567 M
Total Current Liabilities 7.355 M 16.253 M
Total Non Current Liabilities 4.019 M 0
Total Liabilities 11.374 M 16.253 M
Net Assets 25.131 M 35.314 M
Breakdown 30/06/2021 30/06/2020
Net Operating Cash -8.835 M 0
Net Invested Cash -5.304 M 0
Net Financing Cash Flows 36.541 M 0
Beginning Cash 100 0
End Cash Position 22.41 M 0
Exchange Rate Adjustments 8,503 0
Other Cash Adjustments 0 0
Ending Cash 22.41 M 0

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK